Citadel Advisors
TCRX icon

Citadel Advisors’s TScan Therapeutics TCRX Stock Holding History

Citadel Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Buy
1,009,107
+690,696
+217% +$736K ﹤0.01% 8220
2026
Q1 		$322K Buy
318,411
+155,534
+95% +$166K ﹤0.01% 10317
2025
Q4 		$163K Sell
162,877
-227,870
-58% -$330K ﹤0.01% 11220
2025
Q3 		$711K Buy
390,747
+171,760
+78% +$304K ﹤0.01% 8300
2025
Q2 		$318K Buy
218,987
+164,595
+303% +$238K ﹤0.01% 9684
2025
Q1 		$75.1K Sell
54,392
-88,225
-62% -$191K ﹤0.01% 11830
2024
Q4 		$434K Buy
+142,617
New +$646K ﹤0.01% 8877
2024
Q3 		– Sell
-157,963
Closed -$924K – 15235
2024
Q2 		$924K Buy
157,963
+146,531
+1,282% +$1.15M ﹤0.01% 6746
2024
Q1 		$90.8K Buy
+11,432
New +$71.9K ﹤0.01% 11487
2021
Q4 		– Sell
-11,922
Closed -$99K – 14743
2021
Q3 		$99K Buy
+11,922
New +$111K ﹤0.01% 12887

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors's TCRX Position: Q2 2026 in Review

Citadel Advisors increased its TScan Therapeutics (TCRX) stake by 217% in Q2 2026, buying an estimated $736K and bringing the position to 1,009,107 shares worth $989K. The position accounts for ﹤0.01% of the portfolio, ranked #8220.

Citadel Advisors first reported a position in TCRX in Q3 2021 and has held it in 10 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Citadel Advisors held 1,009,107 shares of TScan Therapeutics worth $989K as of Q2 2026.
  • Citadel Advisors bought 690,696 TScan Therapeutics shares in Q2 2026, an estimated $736K.
  • TScan Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8220 holding.
  • Citadel Advisors first reported a position in TScan Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.